Physician profile
Muneera Atcha
NPI 1154611796
$9,467.63
in general payments reported to CMS, 2019-2025
41 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $758 · 2021: $1,316 · 2022: $1,230 · 2023: $1,310 · 2024: $1,610 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,567.36 |
| Education | $323.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,075.93 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,050.94 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Janssen Biotech, INC. | $832.31 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $828.42 | 2019-2025 | |
| Pfizer INC. | $675.22 | 2019-2024 | |
| Glaxosmithkline, LLC. | $495.80 | 2019-2025 | Benlysta, Nucala |
| Ucb, INC. | $365.87 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $273.60 | 2020-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $187.53 | 2020-2025 | Orencia |
| Mallinckrodt Enterprises LLC | $185.04 | 2019 | |
| Octapharma USA, INC. | $126.44 | 2024-2025 | Octagam Immune Globulin (Human) |
| Aurinia Pharma U.S., INC. | $103.30 | 2023-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $98.43 | 2019-2022 | |
| Sandoz INC. | $95.89 | 2023-2024 | Hyrimoz |
| Horizon Therapeutics Plc | $83.82 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muneera Atcha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.